4.7 Article

Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 70, 期 3, 页码 891-898

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dku465

关键词

target attainment rate; free concentration; continuous veno-venous haemofiltration; tolerance; Monte Carlo simulations; ESBLs

资金

  1. Eumedica s.a.
  2. Belgian Fonds de la Recherche Scientifique Medicale
  3. Belgian Region Wallonne

向作者/读者索取更多资源

Objectives: The growing incidence of infections caused by Enterobacteriaceae producing ESBLs has led to increased use of carbapenems. Temocillin, which resists most beta-lactamases, may be a useful alternative. The aim of this study was to assess the pharmacokinetics and target attainment rates of 6 g of temocillin daily divided into three administrations every 8 h (three times daily) or administered by continuous infusion in critically ill patients. Patients and methods: This was a prospective, two-centre, randomized, controlled study in patients with intra-abdominal or lower respiratory tract infections caused by Enterobacteriaceae. Results: Thirty-two patients were included and analysed for clinical efficacy, and pharmacokinetics were measured in 29 of them. Four patients undergoing continuous veno-venous haemofiltration (CVVH) were analysed separately. Mean, median and range of percentages of the dosing interval during which the free drug concentration remained >16 mg/L were 76.4, 98 and 18.7-98.9 in patients treated three times daily and 98.9, 89.7 and 36.4-99.9 in patients with continuous infusion, respectively. Clinical cure rates were 79% and 93% in each of these groups, respectively (not significant). Patients with CVVH received a daily dose of 750 mg given by continuous infusion and had a mean free drug concentration of only 13.8 +/- 1.9 mg/L. No adverse event attributable to temocillin was observed. Conclusions: Temocillin (6 g daily) given by continuous infusion allows a larger proportion of critically ill patients to have free drug serum concentrations covering infections caused by Enterobacteriaceae with an MIC of 16 mg/L compared with administration three times daily. Clinical efficacy compared with carbapenems in documented severe infections needs to be further studied.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Management of COVID-19 Coagulopathy in a Patient with Severe Haemophilia A

Joao Pinto Pereira, Philippe Hantson, Ludovic Gerard, Xavier Wittebole, Pierre-Francois Laterre, Catherine Lambert, Cedric Hermans

Summary: A 54-year-old man with severe haemophilia A, also suffering from COVID-19 infection and multiple risk factors, received treatment in ICU with efmoroctocog alpha and low-molecular-weight heparin without experiencing thrombosis or hemorrhage in different organs during post-mortem examination.

ACTA HAEMATOLOGICA (2021)

Article Critical Care Medicine

Acute Effects of Sitting Out of Bed and Exercise on Lung Aeration and Oxygenation in Critically Ill Subjects

Cheryl E. Hickmann, Natalia R. Montecinos-Munoz, Diego Castanares-Zapatero, Ricardo S. Arriagada-Garrido, Ursula Jeria-Blanco, Timour Gizzatullin, Jean Roeseler, Jonathan Dugernier, Xavier Wittebole, Pierre-Francois Laterre

Summary: Early mobilization with a sitting position and exercise in critically ill patients was found to increase lung aeration and improve oxygen levels, especially in more severely hypoxemic subjects.

RESPIRATORY CARE (2021)

Review Biochemistry & Molecular Biology

A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients

Alan Abdulla, Tim M. J. Ewoldt, Ilse M. Purmer, Anouk E. Muller, Diederik Gommers, Henrik Endeman, Birgit C. P. Koch

Summary: This narrative review highlights the challenges in predicting antibiotic pharmacokinetics in critically ill patients, emphasizing the need for individualized dosing regimens and therapeutic drug monitoring. Predictors such as male gender, younger age, and augmented renal clearance play a significant role in determining target non-attainment, suggesting the importance of further investigations to develop optimal dosing algorithms for beta-lactam therapy.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)

Article Critical Care Medicine

Prone Positioning in Spontaneously Breathing Subjects With Moderate or Severe ARDS During Invasive Ventilation

Adil Wiart, Diego Castanares-Zapatero, Xavier Wittebole, Guillaume Maerckx, Guillaume David, Pierre-Francois Laterre, Ludovic Gerard

Summary: The study retrospectively reviewed the experience of placing intubated patients with moderate to severe ARDS in the prone position, finding that prone positioning during pressure support ventilation significantly improved arterial oxygenation and reduced the use of neuromuscular blocking agents.

RESPIRATORY CARE (2021)

Article Medical Laboratory Technology

Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study

Tim M. J. Ewoldt, Alan Abdulla, Nicole G. M. Hunfeld, Anouk E. Muller, Diederik Gommers, Suzanne Polinder, Birgit C. P. Koch, Henrik Endeman

Summary: This study found that target attainment for beta-lactam antibiotics in ICU patients shows a trend towards higher total costs, which can be attributed to the costs of long ICU stays and renal replacement therapy.

THERAPEUTIC DRUG MONITORING (2022)

Article Infectious Diseases

Nitrofurantoin 100 mg versus 50 mg prophylaxis for urinary tract infections, a cohort study

Thijs ten Doesschate, Kelly Hendriks, Cornelis Henri van Werkhoven, Evelien C. van der Hout, Tamara N. Platteel, Irene A. M. Groenewegen, Anouk E. Muller, Andy I. M. Hoepelman, Marc J. M. Bonten, Suzanne E. Geerlings

Summary: This study compares the effectiveness and safety of daily prophylaxis with 50 mg or 100 mg nitrofurantoin for recurrent urinary tract infection. The results show that there is no significant difference in the risk of UTI or pyelonephritis between the two dosages, but there is a higher risk of cough, dyspnea, and nausea with the 100 mg dosage.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Review Medical Laboratory Technology

Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome

Birgit C. P. Koch, Anouk E. Muller, Nicole G. M. Hunfeld, Brenda C. M. de Winter, Tim M. J. Ewoldt, Alan Abdulla, Henrik Endeman

Summary: Early initiation of antibiotics and correct dosing are essential for improving infections in critically ill patients. However, the altered pharmacokinetic parameters and less susceptible microorganisms pose challenges to ensuring optimal antibiotic exposure. Therapeutic drug monitoring (TDM) is a commonly used strategy to support individualized dosing of antibiotics. This review recommends implementing TDM for glycopeptides and aminoglycosides, and suggests performing TDM in specific patient cases for antibiotics such as beta-lactams, fluoroquinolones, and linezolid. Future possibilities for improving TDM include model-informed precision dosing and the use of rapid bioanalytical techniques or biosensors for real-time monitoring of drug concentrations.

THERAPEUTIC DRUG MONITORING (2022)

Review Medical Laboratory Technology

Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review

Alan Abdulla, Puck van den Broek, Tim M. J. Ewoldt, Anouk E. Muller, Henrik Endeman, Birgit C. P. Koch

Summary: This study provides an overview of the current practices of beta-lactam therapeutic drug monitoring (TDM) and identifies barriers and facilitators in its clinical implementation. The main barriers include insufficient knowledge and unavailability of assays, while doubts about cost-effectiveness and clinical effectiveness hinder its broad implementation. Collaboration between physicians and clinical pharmacists and microbiologists can improve physicians' willingness to use beta-lactam TDM.

THERAPEUTIC DRUG MONITORING (2022)

Review Pharmacology & Pharmacy

Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review

Fleur M. Keij, Gerdien A. Tramper-Stranders, Birgit C. P. Koch, Irwin K. M. Reiss, Anouk E. Muller, Rene F. Kornelisse, Karel Allegaert

Summary: The pharmacokinetics of clavulanic acid in pediatric patients is highly variable, similar to reports in adults, but more pronounced. There is a lack of knowledge regarding the specific population-specific explanation for this variability. Model-based pharmacokinetic studies addressing maturational and disease-specific changes in the pediatric population as well as additional pharmacodynamic studies are needed to define a clear target.

CLINICAL PHARMACOKINETICS (2022)

Article Infectious Diseases

Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing

Eveline E. Roelofsen, Brenda C. M. de Winter, Heleen van der Spek, Susan Snijders, Birgit C. P. Koch, Sanne van den Berg, Anouk E. Muller

Summary: For decades, flucloxacillin has been used to treat methicillin-susceptible Staphylococcus aureus (MSSA). This study aimed to determine the pharmacokinetic/pharmacodynamic (PK/PD) index and the required PD-index value for efficacy. The results provide insights for optimizing dosing regimens in humans.

ANTIBIOTICS-BASEL (2022)

Article Microbiology

Pharmacodynamics of Temocillin in Neutropenic Murine Infection Models

Anouk E. E. Muller, Merel Raaphorst, Aart van der Meijden, Brenda C. M. de Winter, Joseph Meletiadis, Sanne van den Berg

Summary: This study investigated the pharmacokinetics of temocillin in plasma and epithelial lining fluid in infected neutropenic mice, and determined the exposure-response relationships for Escherichia coli and Klebsiella pneumoniae. The results showed that temocillin achieved a static effect in the lung infection model with a lower median %fT>MIC compared to the thigh infection model, indicating its potential use in patients with pneumonia.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Infectious Diseases

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models

Aart van der Meijden, Vincent Aranzana-Climent, Heleen van der Spek, Brenda C. M. de Winter, William Couet, Joseph Meletiadis, Anouk E. Muller, Sanne van den Berg

Summary: In this study, the pharmacokinetics and pharmacodynamics of polymyxin B were determined in neutropenic infected mice. The fAUC/MIC index was found to best describe the drug’s effectiveness. However, the standard dosing regimen did not achieve the PK/PD targets for the majority of clinical isolates, suggesting that polymyxin B may be ineffective as monotherapy for serious infections.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?

Letao Li, Sebastiaan D. T. Sassen, Tim M. J. Ewoldt, Alan Abdulla, Nicole G. M. Hunfeld, Anouk E. Muller, Brenda C. M. de Winter, Henrik Endeman, Birgit C. P. Koch

Summary: The suitability of published meropenem pharmacokinetic models for clinical practice was evaluated using real-world ICU data, and two models were found to perform well when using two to three plasma concentrations for therapeutic drug monitoring, while the other models performed poorly.

ANTIBIOTICS-BASEL (2023)

Article Microbiology

In Vitro-In Vivo Correlation of Posaconazole-Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels

Joseph Meletiadis, Maria-Ioanna Beredaki, Antigoni Elefanti, Spyros Pournaras, Anouk Muller

Summary: In order to evaluate the efficacy of combination therapy, it is necessary to study the correlation between in vitro and in vivo testing. This study attempted to correlate the in vitro chequerboard testing of posaconazole and amphotericin B with the in vivo outcome of combination therapy. The results showed consistency between the in vitro and in vivo testing.

JOURNAL OF FUNGI (2023)

Article Infectious Diseases

Empirical use of temocillin in hospitalized patients: results from a retrospective audit

Hala Kandil, Robert M. Gray, Rakan El-Hamad, Madhuri Vidwans, Tejal Vaghela, Omar Naji, Sebastien van de Velde

Summary: After a shortage of piperacillin/tazobactam, a large hospital in England replaced it with temocillin and found that treatment with temocillin resulted in a clinical success rate of 88.9%.

JAC-ANTIMICROBIAL RESISTANCE (2023)

暂无数据